Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13,036 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.
He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, Liu J, Zhang X, Zhang X, Jin Y, Wang Y, Zhang S, Zhu L, Jacob A, Jia R, You X, Li X, Li C, Zhou Y, Yang Y, Ye H, Liu Y, Su Y, Shen N, Alexander J, Guo J, Ambrus J, Lin X, Yu D, Sun X, Li Z. He J, et al. Among authors: yu d. Ann Rheum Dis. 2020 Jan;79(1):141-149. doi: 10.1136/annrheumdis-2019-215396. Epub 2019 Sep 19. Ann Rheum Dis. 2020. PMID: 31537547 Free PMC article. Clinical Trial.
Characteristics of Sjögren's syndrome in rheumatoid arthritis.
He J, Ding Y, Feng M, Guo J, Sun X, Zhao J, Yu D, Li Z. He J, et al. Among authors: yu d. Rheumatology (Oxford). 2013 Jun;52(6):1084-9. doi: 10.1093/rheumatology/kes374. Epub 2013 Feb 4. Rheumatology (Oxford). 2013. PMID: 23382356
Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure.
He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, Sun X, Vandenberg K, Rockman S, Ding Y, Zhu L, Wei W, Wang C, Karnowski A, Belz GT, Ghali JR, Cook MC, Riminton DS, Veillette A, Schwartzberg PL, Mackay F, Brink R, Tangye SG, Vinuesa CG, Mackay CR, Li Z, Yu D. He J, et al. Among authors: yu d. Immunity. 2013 Oct 17;39(4):770-81. doi: 10.1016/j.immuni.2013.09.007. Immunity. 2013. PMID: 24138884 Free article.
Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.
He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, Xu C, Hou Z, Leong YA, Zhu L, Feng J, An Y, Jia Y, Li C, Liu X, Ye H, Ren L, Li R, Yao H, Li Y, Chen S, Zhang X, Su Y, Guo J, Shen N, Morand EF, Yu D, Li Z. He J, et al. Among authors: yu d. Nat Med. 2016 Sep;22(9):991-3. doi: 10.1038/nm.4148. Epub 2016 Aug 8. Nat Med. 2016. PMID: 27500725
The rise of IL-2 therapy - a picture beyond Treg cells.
Li Z, He J, Yu D. Li Z, et al. Among authors: yu d. Nat Rev Rheumatol. 2017 Jun;13(6):386. doi: 10.1038/nrrheum.2017.70. Epub 2017 May 11. Nat Rev Rheumatol. 2017. PMID: 28490785 No abstract available.
The metabolic hormone leptin promotes the function of TFH cells and supports vaccine responses.
Deng J, Chen Q, Chen Z, Liang K, Gao X, Wang X, Makota FV, Ong HS, Wan Y, Luo K, Gong D, Yu X, Camuglia S, Zeng Q, Zhou T, Xue F, He J, Wei Y, Xiao F, Ma J, Hill DL, Pierson W, Nguyen THO, Zhou H, Wang Y, Shen W, Sun L, Li Z, Xia Q, Qian K, Ye L, Rockman S, Linterman MA, Kedzierska K, Shen N, Lu L, Yu D. Deng J, et al. Among authors: yu d, yu x. Nat Commun. 2021 May 24;12(1):3073. doi: 10.1038/s41467-021-23220-x. Nat Commun. 2021. PMID: 34031386 Free PMC article.
Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.
Zhou P, Chen J, He J, Zheng T, Yunis J, Makota V, Alexandre YO, Gong F, Zhang X, Xie W, Li Y, Shao M, Zhu Y, Sinclair JE, Miao M, Chen Y, Short KR, Mueller SN, Sun X, Yu D, Li Z. Zhou P, et al. Among authors: yu d. PLoS Pathog. 2021 Oct 7;17(10):e1009858. doi: 10.1371/journal.ppat.1009858. eCollection 2021 Oct. PLoS Pathog. 2021. PMID: 34618873 Free PMC article.
13,036 results
You have reached the last available page of results. Please see the User Guide for more information.